Finance

Stocks making the biggest moves midday: Nike, Corcept Therapeutics, Taiwan Semiconductor &

EA Builder

Check out the companies making the biggest moves midday: Nike — Shares of the sneaker giant rose around 4% after board members Tim Cook and Robert Holmes Swan, as well as Nike CEO Elliott Hill, increased their stakes, Verity data shows. The action comes as Nike wraps up a tough year. Corcept Therapeutics — Shares plummeted 50% after the U.S. Food and Drug Administration did not approve of Corcept’s drug relacorilant as a treatment for patients with hypercortisolism. The FDA decided it couldn’t reach a favorable benefit-risk assessment for the drug without the company providing further evidence of effectiveness. Molina Healthcare — The insurer rose 2.7%, putting it on track for its fourth straight positive session and up 6.3% for the week. Molina got a boost this week after famed investor Michael Burry highlighted the company in a Substack post. Nvidia — The chipmaker rose 0.7%, adding to its stellar year of gains. For 2025, Nvidia is up 40%. Vanda Pharmaceuticals — The biopharma company surged 25% after the FDA approved tradipitant, a drug aimed at treating vomiting induced by motion. Taiwan Semiconductor Manufacturing — Shares ticked up 2% after Reuters reported that Nvidia asked the semiconductor firm to boost its H200 production in response to Chinese orders exceeding 2 million units for 2026. Hyatt Hotels — The hotel chain dropped more than 1% after updating its 2025 outlook due to Hurricane Melissa, which struck Jamaica in October. The company said it expects adjusted EBITDA to be at the low end of a $1.09 billion-$1.11 billion range. — CNBC’s Darla Mercado, Liz Napolitano and Alex Harring contributed reporting.

This article was originally published by a Cnbc.com. Read the Original article here. .

Share with your friends!

Leave a Reply

Your email address will not be published. Required fields are marked *

Get The Latest Investing Tips
Straight to your inbox

Subscribe to our mailing list and get interesting stuff and updates to your email inbox.

Thank you for subscribing.

Something went wrong.